The “2021 Retinal Pharmaceuticals Market Report” features an updated disease prevalence model by ethnicity and now covers more development-stage categories, therapies, and companies. The report features new discussions of gene therapy delivery methods; DR, PDF, and NPDR treatment in the US; pharmaceutical treatment for vitreous hemorrhage; plans for Beovu use in the US; and potentially disruptive technologies. Sales forecasts through 2026 have been refreshed following the COVID-19 pandemic and also with an outlook for sustained drug delivery.
In addition to profiles of 33 market competitors, the report also covers 161 companies that have retina pharmaceuticals and biologics in very early development; early-stage companies that have out-licensed retina drug candidates; and companies with drug delivery technologies in development that may be applicable to retina.
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.